NeuroThree Therapeutics

China-based Jiangsu Nhwa Pharmaceutical Co., Ltd (SHE: 002262) announced plans to subscribe to Hong Kong-headquartered NeuroThree Therapeutics, Inc.’s Pre-Series A financing round, investing USD 3.5 million for 12.5 million shares. Upon completion of the transaction, Nhwa will hold a 10.448% stake in NeuroThree. Company BackgroundFounded in 2021, NeuroThree focuses on…